NOW Foods Berberine Glucose Support Review

It's the delivery carrier, not a second active ingredient. NOW's front label reads 'Combined with MCT Oil for Optimal Berberine Absorption' — 700 mg of medium-chain triglyceride oil per softgel, 238 mg of which is capric acid (C10), the kind of lipid base used in self-emulsifying delivery systems for poorly water-soluble compounds. Berberine's oral bioavailability is famously low (~1%, per Liu 2016), driven mostly by P-glycoprotein efflux and rapid gut metabolism rather than poor lipid solubility, so a fat carrier isn't an obvious fix for berberine specifically — it's a plausible mechanism, not a proven one, and NOW hasn't published pharmacokinetic data for this exact formula. What the MCT oil isn't: a second glucose-support active. There's no alpha-lipoic acid or cinnamon in this formula, and no separate glucose-related claim is made for the oil itself.

Two reasons. First, softgels reduce GI irritation versus hard capsules for some users — the gel shell dissolves more gradually, smoothing peak luminal concentration. Second, the softgel format is what lets NOW carry the berberine dose in the 700 mg MCT oil base the front label markets for absorption — an oil carrier doesn't suspend well in a dry hard capsule. Trade-off: softgels ship larger than an equivalent hard cap, because the oil carrier adds bulk, and some users find the gelatin shell harder to swallow than HPMC veggie caps.

Not that we could find. NOW's front label makes the claim, but the company hasn't published a head-to-head pharmacokinetic trial comparing this MCT-oil softgel against a plain dry-cap berberine HCl bottle. The mechanism is plausible in general — lipid-based, self-emulsifying delivery systems have improved absorption for some poorly water-soluble compounds in other contexts — but berberine's own poor bioavailability is driven more by P-glycoprotein efflux and first-pass gut metabolism than by lipid solubility, so it's not obvious an oil carrier moves the needle much. Treat the claim as a reasonable formulation choice, not a documented multiplier on your effective dose.

Talk to your prescriber before you do. Berberine itself has glucose-lowering activity that can be additive with metformin, sulfonylureas, or other diabetes medications, raising hypoglycemia risk in some users — a real interaction concern independent of any adjunct ingredient, and this formula doesn't contain alpha-lipoic acid or cinnamon to compound it. If you're already taking a different berberine-containing product — including some GLP-1-support combo formulas that quietly include berberine — track your total daily berberine dose across bottles so you don't unintentionally stack it.

800 mg/day sits well below the Yin 2008 trial anchor of 1,500 mg/day. To hit clinical dose, you'd need 4 softgels (1,600 mg berberine, a bit above the Yin 2008 anchor) — straightforward to scale up since there's no second active to overshoot, though softgels are large and 4/day is a real swallow-count commitment. Lan 2015's broader meta found partial effects reproduce at doses below 1,500 mg/day, so 800 mg/day isn't nothing — it's a lower-effective-range dose, not a clinical-dose match. For pure berberine at clinical dose in fewer capsules, jump to Solaray (500 mg/cap × 3) or Nutricost (600 mg/cap).

NOW's in-house QC is genuinely above-baseline for the household-brand tier — an NSF-registered facility, in-house labs that run identity/purity testing on every batch, and a 30-year zero-major-recall track record, plus independent consumer-lab verification (ConsumerLab.com, LabDoor). That's a real structural advantage over brands running GMP-baseline QC with no in-house testing claim. Where NOW gives ground back is dose and format: at 400 mg berberine per softgel, you need more softgels to reach Yin 2008's 1,500 mg/day clinical anchor than a 500 mg-per-capsule bottle does, and the MCT-oil 'optimal absorption' carrier is a plausible but unverified marketing claim rather than a documented edge. Brand trust and QC pedigree are NOW's differentiators here, not dose efficiency.

1. [1] Yin 2008 PMID 18442638 — Efficacy of berberine in patients with type 2 diabetes mellitus. Berberine 500 mg 3×/day (HCl form) for 3 months matched metformin 1,500 mg/day on HbA1c, fasting glucose, and postprandial glucose. NOW's default 800 mg/day (2 softgels) sits below this trial anchor; full clinical-dose protocols require 4 softgels/day (1,600 mg).
2. [2] Lan 2015 PMID 25498346 — Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Pooled analysis of 27 RCTs (n=2,569) at berberine 1,000-1,500 mg/day showing LDL −25%, triglycerides −35%, glucose improvements. NOW's 800 mg/day berberine sits below the trial window but partial response is documented.
3. [3] Liu 2016 PMID 26851175 — Research progress on berberine with a special focus on its oral bioavailability. Comprehensive review confirming ~1% oral bioavailability for berberine HCl. The MCT-oil softgel format NOW uses doesn't have published bioavailability data specific to this formula but may smooth peak luminal concentration, improving GI tolerance.
4. [4] Pérez-Rubio 2013 PMID 23808999 — Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Berberine 500 mg 3×/day for 3 months in metabolic-syndrome subjects improved insulin sensitivity (Matsuda index), waist circumference, triglycerides, and systolic blood pressure. NOW's berberine dose (800 mg/day default) targets this metabolic-syndrome use case, though below Pérez-Rubio's 1,500 mg/day trial dose.